Distinguishing inflammatory bowel disease from small cell intestinal lymphoma in cats is clinically critical but requires definitive biopsy. Understanding the diagnostic pathway enables informed decision-making.
Misdiagnosis between IBD and small cell lymphoma does not necessarily change initial treatment but critically affects prognosis communication and long-term monitoring strategy. A cat told it has IBD when it actually has lymphoma may not receive appropriate monitoring for progression. A cat whose owner expects lymphoma-level prognosis when they have IBD may have unnecessary distress. Accurate diagnosis through appropriate biopsy reduces uncertainty and enables welfare-optimal management decisions.